![](https://www.microbiometimes.com/wp-content/uploads/2022/06/shutterstock_1334699582-326x245.jpg)
4D pharma Receives Notice of Delisting From Nasdaq
Source: 4D Pharma 4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announced that on June 27, 2022, it received written […]